Regan J. Lauer - Dec 15, 2023 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
Chief Accounting Officer
Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Stock symbol
IBRX
Transactions as of
Dec 15, 2023
Transactions value $
$0
Form type
4
Date filed
12/19/2023, 04:41 PM
Previous filing
Sep 6, 2023
Next filing
Feb 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +21K +39.02% $0.00 74.9K Dec 15, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -21K -50% $0.00 21K Dec 15, 2023 Common Stock 21K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through each applicable vesting date, the restricted stock units ("RSUs") will vest as follows: 1/3rd of the RSUs subject to the award shall vest June 15, 2023, 1/3rd of the RSUs subject to the award shall vest December 15, 2023, and 1/3rd of the RSUs subject to the award shall vest December 15, 2024 such that the award shall be fully vested on December 15, 2024.